Connect Biopharma Holdings Limited (CNTB)
NGM · Healthcare · Biotechnology
$2.04
-0.97%
Closing price as of 2026-09-11 · Source: TEK2day Finance
Key Metrics
Market Cap
$128.5M
Shares Outstanding
63.0M
P/S (TTM)
43.5x
Exchange
NGM
Currency
USD
About Connect Biopharma Holdings Limited
Connect Biopharma Holdings Limited operates as a clinical-stage biopharmaceutical company in the United States. It develops rademikibart, a human monoclonal IgG4 antibody directed against IL-4Ra in two Phase 2 trials for the treatment of acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD). The company was founded in 2012 and is headquartered in San Diego, California.
Quarterly Financials
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 16K | 0.00 | 169K | 2.8M |
| Operating Income | (17.7M) | (15.5M) | (19.6M) | (17.6M) |
| Net Income | (17.2M) | (15.1M) | (19.4M) | (17.3M) |
| Diluted EPS | $-0.31 | $-0.27 | $-0.34 | $-0.27 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 26.0M | 64K |
| Operating Income | (116.5M) | (69.1M) | (22.5M) | (58.1M) |
| Net Income | (118.1M) | (62.1M) | (15.6M) | (55.5M) |
| Diluted EPS | $-2.10 | $-1.13 | $-0.28 | $-1.00 |